Adcetris brentuximab vedotin: Completed Phase III enrollment

Seattle Genetics completed enrollment of 132 patients who received prior systemic therapy in the open-label, international Phase III ALCANZA trial comparing 1.8 mg/kg IV Adcetris once every 21 days vs. physician’s choice of methotrexate or bexarotene. The company has an SPA from FDA for the trial. Adcetris is approved to treat forms of Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). ...